Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 18 January 2019, 13:33 HKT/SGT
Share:
    

Source: Eisai
Eisai's Notification Regarding Results of Voluntary Retirement Program

TOKYO, Jan 18, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that the application period for the first round of the voluntary retirement program it announced on October 25, 2018, has ended and hereby discloses the results as follows:

1. Outline of Voluntary Retirement Program
a) Eligibility Criteria:
Employees 45 or older who have worked at Eisai for five consecutive years or more as of April 1, 2018
b) Effective Date of Retirement:
First round: March 31, 2019; Second round: March 31, 2020;
Third round: March 31, 2021
c) Number of Applicants Sought:
First round: Approximately 100*
d) Application Period:
First round: From December 11, 2018 to December 21, 2018 (may be subject to change based on the application situation). The application periods for the second and third rounds will cover a similar period of time each fiscal year.
e) Preferential Conditions:
A premium will be added to the normal retirement allowance. In addition, applicants will also have the option to receive job-placement assistance.

*The number of applicants sought for the second and third round will be determined in consideration of the outcome of the application situation.

2. Number of Confirmed Applicants / Total Amount of Premium Retirement Payments (First Round)
a) Number of Confirmed Applicants:
300 applicants
b) Total Amount of Premium Retirement Payments:
Approx. 6.6 billion yen

*Judging from the application situation, the application deadline was shortened from December 21, 2018 to December 19, 2018.

3. Impact on Financial Performance
The sum total of premium retirement payments associated with the implementation of the first round of this program will be recorded as expenses in the settlement of accounts for the third quarter of the fiscal year ending March 31, 2019. The full-year consolidated financial results forecasts for the fiscal year ending March 31, 2019 previously announced on November 1, 2018 includes a certain level for these expenses, and based on recent trends in business performance and other factors, there is no change to the full-year consolidated financial results forecasts.


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120


Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Dec 11, 2025 18:41 HKT/SGT
Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year
Dec 9, 2025 17:51 HKT/SGT
"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List
Dec 4, 2025 17:36 HKT/SGT
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025
Dec 3, 2025 17:19 HKT/SGT
New Data Presented at CTAD 2025 Confirms Pharmacological Effect of LEQEMBI(R) (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
Dec 2, 2025 23:01 HKT/SGT
Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
Nov 28, 2025 22:00 HKT/SGT
Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the Treatment of Early Alzheimer's Disease in Japan
Nov 26, 2025 18:42 HKT/SGT
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
Nov 17, 2025 21:08 HKT/SGT
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom
Oct 30, 2025 13:43 HKT/SGT
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
Oct 28, 2025 23:30 HKT/SGT
Merck & Co., Inc. and Eisai Announce WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: